Introduction {#sec1-1}
============

*Enterococcus*, a normal commensal of human gastrointestinal and genitourinary tract, is now increasingly being recognized as one of the causative agents of healthcare-associated infections such as surgical site infections and urinary tract infections over the past few decades.\[[@ref1][@ref2]\] The management of infections secondary to *Enterococcus* species (*Enterococcus*. spp) is difficult because *Enterococcus* not only possesses intrinsic resistance to many antimicrobial agents but also has the ability to acquire resistance against antibiotics through genetic mutation.\[[@ref3]\]

Enterococcal meningitis is very rare among bacterial meningitis and mostly nosocomial in origin.\[[@ref4][@ref5]\] Risk factors for enterococcal meningitis are neurosurgical procedures, underlying immunosuppression, enterococcal infection, or colonization at other sites of the body and central nervous system (CNS) devices.\[[@ref4][@ref5][@ref6]\] CNS infections secondary to *Enterococcus* spp. are associated with high mortality.\[[@ref5][@ref6][@ref7]\]

In this study, we have looked at the clinical features, therapeutic options with antimicrobial susceptibility, and outcomes of enterococcal meningitis in a tertiary care hospital.

Subjects and Methods {#sec1-2}
====================

We retrospectively reviewed medical records of all patients with acute bacterial meningitis admitted to our hospital over the periods of 4 years, i.e., from 2013 to 2016.

Patient\'s clinical records, microbiology and other laboratory data were reviewed. In the present study, the criteria of acute bacterial meningitis were as follows:

Patients with clinical presentation of acute bacterial meningitis including fever, seizure, altered mental status, and headachePositive cerebrospinal fluid (CSF) culture in patients with clinical presentation of acute bacterial meningitis.

CSF parameters:

Leucocytes count ≥10CSF glucose \<2/3 of blood glucose or \<45 mg/dl if no simultaneous blood glucose available.

Nosocomial or healthcare-associated meningitis or ventriculitis was defined as clinical features and CSF findings not present at the time of admission and developed 48 hrs after admission. Mixed infection was defined as at least two or more than two organisms isolated from CSF culture (exclusion criteria of study). The antibiotics susceptibility was based on Clinical Laboratory Standard Institute document M-100.

Results {#sec1-3}
=======

Demographic data {#sec2-1}
----------------

During the study period from years 2013 to 2016, a total of six patients were diagnosed with identified as enterococcal meningitis/ventriculitis including three children (age from 2--12 months) and 3 adults (age range from 40 to 71 years). All patients had single pathogen isolated from CSF that is *Enterococcus*.spp.

Clinical features of the subjects {#sec2-2}
---------------------------------

All of the patients developed meningitis after neurosurgical procedures such as craniotomy, repair of myelomeningocele, and ventriculoperitoneal (VP) shunt. Majority of patients (4 out of 6) had CNS devices *in situ* at the time of development of meningitis. Clinical features and management are given in [Table 1](#T1){ref-type="table"}.

###### 

Clinical data of patients with enterococcal meningitis

  Patient   Age/sex           Infection pattern   Underlying condition                            Clinical features                                    Microorganisms           Treatment with duration                           Outcome
  --------- ----------------- ------------------- ----------------------------------------------- ---------------------------------------------------- ------------------------ ------------------------------------------------- ---------
  1         40 years/female   Nosocomial          Craniotomy secondary to meningioma              Fever, vomiting                                      *Enterococcus* species   Ceftriaxone × 4 days and vancomycin for 14 days   Cured
  2         1 year/male       Nosocomial          MMC repair, VP shunt                            Fever, vomiting                                      VRE                      Meropenem × 5 days, linezolid × 21 days           Cured
  3         2 months/male     Nosocomial          MMC repair, VP shunt                            Fever, neck stiffness, altered conscious level       *Enterococcus* species   Meropenem × 7 days, vancomycin × 21 days          Cured
  4         52 years/female   Nosocomial          DM, craniotomy sec to intracranial bleed, EVD   Fever, headache, vomiting, altered conscious level   *Enterococcus* species   Meropenem × 6 days, vancomycin for 21 days        Cured
  5         1 year/female     Nosocomial          MMC repair                                      Fever, vomiting, seizures                            *Enterococcus* species   Meropenem × 4 days, vancomycin × 14 days          Cured
  6         71 years/female   Nosocomial          Intracranial bleed, EVD                         Fever, altered conscious level                       VRE                      Linezolid × 27 days and rifampicin × 17 days      Cured

MMC -- Myelomeningocele; VP shunt -- Ventriculo-peritoneal shunt; VRE -- Vancomycin resistant *Enterococcus*; DM -- Diabetes mellitus; EVD -- External ventricular drainage

Organism isolated and antibiotic sensitivity and resistance {#sec2-3}
-----------------------------------------------------------

Blood cultures and other body site cultures were negative for *Enterococcus* as well as other organisms. The causative organism isolated from CSF culture of all patients was *Enterococcus* spp. only and none of the patients had mixed bacterial infection. The organism was present in Gram stain of CSF and isolated on blood agar culture medium. It was identified by conventional biochemical reactions, API 20 STREP (BIOMERIEUX), and its intrinsic resistance to ceftriaxone and clindamycin. The antibiotic susceptibility was checked on Muller-Hinton agar by disk diffusion method and vancomycin minimum inhibitory concentration was checked with E-strip (gradient diffusion method).

In all patients, *Enterococcus* spp. was resistant to ampicillin, Amoxicillin-clavulanate, and oxytetracycline. Vancomycin-resistant *Enterococcus* (VRE) was also isolated in CSF of two of our patients; however, VRE strains showed sensitivity to linezolid and chloramphenicol.

Outcome {#sec2-4}
-------

All patients treated with antibiotics according to culture and sensitivities and cured as repeat CSF cultures were negative. Only two patients became neurologically dependent because of their associated neurological condition and no mortality reported in the current case series.

Discussion {#sec1-4}
==========

Postoperative CNS infection after neurosurgical procedures is a serious problem with a reported incidence of 0.8%--8%.\[[@ref8][@ref9][@ref10][@ref11]\] The common bacterial pathogens associated with nosocomial meningitis after neurosurgical interventions are *Staphylococcus aureus*, coagulase-negative *Staphylococcus*, Gram-negative bacilli such as *Pseudomonas aeruginosa*, *Acinetobacter*, and *Propionibacterium acnes*.

Intracranial device can predispose to infections that could be due to contamination and/or colonization of implanted devices.\[[@ref4][@ref5][@ref6]\] Additional risk factors include the presence of infection with *Enterococcus* spp. in other sites of the body, underlying chronic illnesses, and immunosuppressive states such as diabetes and steroids therapy.\[[@ref5][@ref6][@ref12][@ref13]\]

The emergence of resistant *Enterococcus* strains has complicated the management of enterococcal infection. The invasive enterococcal infections such as endocarditis require a combination of cell wall-active agents with other susceptible antimicrobials such as aminoglycoside to achieve synergistic bactericidal activity. The simultaneous use of a cell wall-active agent raises the permeability of the cell so that an intracellular bactericidal concentration of accompanying antibiotic can be achieved.\[[@ref14]\] Even though previously published cases of enterococcal meningitis were treated with beta-lactam, glycopeptides, or other susceptible antibiotics either alone or in combination,\[[@ref5][@ref13]\] vancomycin can be used as a single agent with good clinical response.

Vancomycin-resistant enterococcal meningitis/ventriculitis (VRE meningitis/ventriculitis) is very rare and only reported in the form of case report and case series in literature. Limited therapeutic options are available for vancomycin-resistant CNS infections and best possible therapy has not been established.\[[@ref15][@ref16]\] VRE infections are successfully treated with antibiotics such as linezolid, daptomycin, quinupristin-dalfopristin, rifampicin, and gentamicin.\[[@ref17][@ref18][@ref19]\] The first case of treatment of VRE meningitis with linezolid was reported in 2001. Linezolid has good meningeal penetration and is used alone or in combination with other susceptible antibiotics for VRE meningitis/ventriculitis with favorable clinical outcome.\[[@ref20][@ref21][@ref22][@ref23]\]

Intrathecal or intraventricular antibiotics have been increasingly utilized in cases of nosocomial meningitis/ventriculitis when systemic therapy is unable to sterilize CSF. Antibiotics used for intrathecal or intraventricular route for cases of VRE meningitis/ventriculitis are linezolid, gentamicin, daptomycin, chloramphenicol, and quinupristin/dalfopristin.\[[@ref15][@ref24][@ref25][@ref26][@ref27]\] Removal of infected hardware like VP shunt is also recommended for better treatment outcome.\[[@ref28]\] Although reported mortality is high with enterococcal CNS infection,\[[@ref5][@ref13]\] timely initiation of appropriate therapy improves outcomes.

Conclusions {#sec1-5}
===========

Enterococcal meningitis should be suspected in patients who developed CNS infection during hospital stay, especially after neurosurgical procedures. As enterococcal meningitis is associated with significant mortality, early recognition and appropriate therapeutic intervention have prime importance for good clinical outcome.
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